Key Highlights
- Oversubscribed $2MM funding: Ceretype’s second seed funding round exceeds expectations, promising further advancements in functional MRI technology.
- Noteworthy backers: Led by Cedar Street Group with contributions from Leafy Tunnel, The One Mind Accelerator, and several private investors.
- Innovative end-to-end platform: Ceretype’s proprietary technology aims to revolutionize the accessibility and applicability of fMRI in drug development.
Source: Business Wire
Notable Quotes
- “This investment will allow us to continue to make fMRI more accessible, and to deliver actionable evidence to improve drug discovery and, ultimately, patient care” – Emily Stern, MD, Co-Founder & CEO at Ceretype Neuromedicine
- “Ceretype’s proprietary end-to-end platform brings remarkable innovation to the previous shortcomings of traditional fMRI, unlocking a powerful tool to visualize and study brain circuitry at a scale that has not been possible before” – Paul Francis, Managing Principal at Cedar Street Group
SoH's Take
Ceretype Neuromedicine’s recent closure of an oversubscribed second round of seed financing is not just a financial milestone but a testament to the burgeoning potential and industry confidence in their innovative fMRI technology. As the company continues to forge partnerships and refine its proprietary platform, the implications for neuropsychiatric drug development and patient care are immense. By focusing on making fMRI more accessible and actionable, Ceretype is poised to significantly impact how neurological disorders are diagnosed, treated, and understood. With a strong leadership team and the backing of influential investors, the future looks bright for Ceretype and the field of functional neuroimaging.
